AzTrials
AzTrials

AgingNCT07356700

Deciphering the Factors of Longevity Through a Multi-Omics Study in Long-Lived Individuals in Hong Kong

An observational study of Aging, run by Hong Kong University of Science and Technology at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Population aging is changing societal dynamics and poses significant global challenges. By 2050, an estimated 1.6 billion people worldwide will be over age 65. Because aging is the primary risk factor for many common chronic diseases, it is essential to reduce the burden of age-related illnesses and promote healthy… Read more about this study

Who is it for?
Ages 65 years and olderHealthy volunteers can take part
Conditions the study is for
Aging
What is being tested?
Observational
How many people
2,500 participants
Where
1 siteChina
Study dates
1 Mar 2026to 28 Feb 2031
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • Healthy volunteers accepted
  • Older adult

Study population: Elderly with extreme longevity (aged >=95 years old)

Who may be able to join

  • Han Chinese ethnicity
  • Able to provide official evidence for being 95 years or older (e.g., a birth certificate)
  • Mentally capable of consenting to join the study with or without informant presence
  • Consent to donation of biospecimens (i.e., blood)

Who cannot join

  • Mentally incapable of consenting to join the study even with the presence of an informant
  • Refusal to provide blood samples

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Nancy Ip, PhD contact

+852-23587304

boip@ust.hk

Hiu Yi Wong, PhD contact

+852-23587344

annawong@ust.hk

China1 site, 1 recruiting

  • Hong Kong University of Science and Technology

    Hong Kong

    Nancy Ip, PhD, +852-23587304, boip@ust.hk

    Hiu Yi Wong, PhD, +852-23587344, annawong@ust.hk

    Recruiting

Other trials in China

About this study

Population aging is changing societal dynamics and poses significant global challenges. By 2050, an estimated 1.6 billion people worldwide will be over age 65. Because aging is the primary risk factor for many common chronic diseases, it is essential to reduce the burden of age-related illnesses and promote healthy aging. Hong Kong has one of the largest proportions of elderly adults and has the highest life expectancy in the world, with approximately 11,575 centenarians reported in 2021. Thus, the long-lived population in Hong Kong is a valuable resource for studying healthy aging.

Longevity is a complex trait influenced by genetic, environmental, and behavioral factors. To unveil the mechanisms leading to longevity and healthy aging, researchers focused on centenarians who are extremely long living. Comparisons between long-lived individuals (LLIs) and others have identified several genetic factors and protein markers associated with longevity. Previous centenarian studies revealed that centenarians and their offsprings have a 5-fold lower risk of developing age-related diseases such as Alzheimer's disease and higher cognitive reserve. Certain protein signatures predict longer survival and centenarians acquire aging signatures much later than elderly in the general population. Certain healthy lifestyle leads to higher chance becoming centenarians, including never smoking, exercise and greater dietary diversity.

Read more

Despite emerging studies on centenarian population, an integrated approach to understand diverse molecular signatures of longevity is still lacking. Moreover, most of the centenarian studies are based on European descents. To conclude, a multi-omics study examining the genetic, proteomic, metabolomic, and microbiota profiles of LLIs in Chinese population is necessary.

Hence, the study proposed herein aims to identify multi-omics biomarkers that can be used to monitor aging processes and related diseases. In addition, it will provide candidate modifiable factors to promote healthy aging, focusing on Chinese population and local Hong Kong population for the first time. Ultimately, the insights gained from this research will inform the development of effective strategies to enhance healthy aging and improve the quality of life of our local aging population.

Read the detailed description

The proposed research is a cross-sectional study that will last for 5 years. 500 individuals aged 95 years or older (i.e., LLIs) from various communities in Hong Kong will be recruited. LLIs will be recruited through advertisements as well as collaboration with geriatric community centers and non-government organizations (NGOs). Participants will be recruited at geriatric centers and NGOs to collect demographic information, family history, medical history, and medication records. Blood samples for clinical chemistry and multi-omics study will be collected. Furthermore, cognitive and functional assessment using various scoring systems will be performed to assess cognition and activities of daily living.

In addition, a control cohort of elderly people (aged 65-94 years, n = 2,000) based on our in-house Alzheimer's disease registry and community cohort will be developed. Accordingly, demographics, clinical profiles, cognitive and functional scores, and multi-omics data between the LLI and control cohorts will be compared.

Conditions
Aging
Being tested
Observational
Keywords
Aging, Multi-omics, AI-based tool, Longevity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ObservationalOther

    Clinical profile, blood collection, cognitive assessment, questionnaires on modifiable risk factors

Study groups in NCT07356700
Study groupRoleWhat they receive
long-lived individuals (LLIs)individuals aged 95 years or older
Receives: Other: Observational
Elderly controlselderly people aged 65-94 years
Receives: Other: Observational

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Biobank of LLIs

    A comprehensive cohort of LLIs with data on demographics, clinical profiles, cognitive and functional assessments, lifestyle, and genomic and proteomic biomarkers

    Measured: 3-5 years

  2. Genetic and modifiable factors associated with longevity

    Genetic and modifiable factors associated with longevity

    Measured: 3-5 years

Secondary outcomes (2)

  1. AI-based model

    AI-based model to elucidate candidate modifiable factors that promote healthy aging

    Measured: 5 years

  2. Healthy aging strategies

    Recommendations for personalized strategies to enhance healthy aging in the elderly population

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2026
  2. Study start1 Mar 2026
  3. Primary completion28 Feb 2031 (estimated)
  4. Study completion28 Feb 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
2,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07356700
Sponsor's protocol ID
HREP-2025-0294
Status last verified
May 2026
First submitted
13 Jan 2026
Last updated
8 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Li Y, Wang K, Jigeer G, Jensen G, Tucker KL, Lv Y, Shi X, Gao X. Healthy Lifestyle and the Likelihood of Becoming a Centenarian. JAMA Netw Open. 2024 Jun 3;7(6):e2417931. doi: 10.1001/jamanetworkopen.2024.17931.

    PubMed 38900423

  • Sebastiani P, Federico A, Morris M, Gurinovich A, Tanaka T, Chandler KB, Andersen SL, Denis G, Costello CE, Ferrucci L, Jennings L, Glass DJ, Monti S, Perls TT. Protein signatures of centenarians and their offspring suggest centenarians age slower than other humans. Aging Cell. 2021 Feb;20(2):e13290. doi: 10.1111/acel.13290. Epub 2021 Jan 29.

    PubMed 33512769

  • Holstege H, Beker N, Dijkstra T, Pieterse K, Wemmenhove E, Schouten K, Thiessens L, Horsten D, Rechtuijt S, Sikkes S, van Poppel FWA, Meijers-Heijboer H, Hulsman M, Scheltens P. The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. Eur J Epidemiol. 2018 Dec;33(12):1229-1249. doi: 10.1007/s10654-018-0451-3. Epub 2018 Oct 25.

    PubMed 30362018

  • Zhang M, Ganz AB, Rohde S, Rozemuller AJM, Bank NB, Reinders MJT, Scheltens P, Hulsman M, Hoozemans JJM, Holstege H. Resilience and resistance to the accumulation of amyloid plaques and neurofibrillary tangles in centenarians: An age-continuous perspective. Alzheimers Dement. 2023 Jul;19(7):2831-2841. doi: 10.1002/alz.12899. Epub 2022 Dec 30.

    PubMed 36583547

  • Tesi N, van der Lee S, Hulsman M, van Schoor NM, Huisman M, Pijnenburg Y, van der Flier WM, Reinders M, Holstege H. Cognitively healthy centenarians are genetically protected against Alzheimer's disease. Alzheimers Dement. 2024 Jun;20(6):3864-3875. doi: 10.1002/alz.13810. Epub 2024 Apr 18.

    PubMed 38634500

  • Hong Kong Centenarian Study 2 Project Report, 2023, Hong Kong Shue Yan University

  • 2021 Thematic Report: Older Persons, HKSAR Census and Statistics Department

Questions about this trial

What is this clinical trial studying?

An observational study of Aging, run by Hong Kong University of Science and Technology at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Nancy Ip, PhD (+852-23587304, boip@ust.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Biobank of LLIs (time frame: 3-5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07356700, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT07356700 | AzTrials